A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label study to evaluate the safety and pharmacokinetics (PK) of three
doses of risperidone-SABER, administered with a needle and syringe or via the DosePro
Needle-Free Delivery System in patients with chronic, stable schizophrenia.